Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection vs Novo Nordisk Semaglutide in Type 2 Diabetes (China, Phase 3)
CTR20222962Phase 3Completed
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), cardiac morbidity, sponsored by Livzon Pharmaceutical Group Inc.. Started Nov 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on CTR20222962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222962.